{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-029687","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.005300+00:00","generated_at":"2026-05-24T01:30:18.807718+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Traws Pharma reports FY2024 net loss of $166.5M; CEO Werner Cautreels retiring, Iain D. Dukes Interim CEO","bullets":["Net loss of $166.5M ($35.21/share) for FY2024, driven by $117.5M acquired IPR&D and $24.4M warrant expense.","Cash, cash equivalents and short-term investments $21.3M as of Dec 31, 2024; cash runway into Q1 2026.","CEO Werner Cautreels retiring as of March 31, 2025; Interim CEO Iain D. Dukes appointed, continuing as Chairman.","Lead candidate tivoxavir marboxil shows positive efficacy in three animal models for H5N1 bird flu; Phase 1 complete; FDA interaction sought under Animal Rule.","R&D expense $12.8M (up $1.4M); G&A expense $12.3M (up $3.2M) for FY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-029687","json":"https://secwatch.observer/filing/0001104659-25-029687.json","markdown":"https://secwatch.observer/filing/0001104659-25-029687.md","text":"https://secwatch.observer/filing/0001104659-25-029687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925029687/0001104659-25-029687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925029687/tm2510891d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:30:18.807718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}